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Pre-amyloid oligomers budding: 
a metastatic mechanism of 
proteotoxicity
Fabrizio Bernini1,*, Daniele Malferrari1,*, Marcello Pignataro1,2, Carlo Augusto Bortolotti1, 
Giulia Di Rocco1, Lidia Lancellotti1, Maria Franca Brigatti1, Rakez Kayed3, Marco Borsari1, 
Federica del Monte2 & Elena Castellini1
The pathological hallmark of misfolded protein diseases and aging is the accumulation of proteotoxic 
aggregates. However, the mechanisms of proteotoxicity and the dynamic changes in fiber formation 
and dissemination remain unclear, preventing a cure. Here we adopted a reductionist approach and 
used atomic force microscopy to define the temporal and spatial changes of amyloid aggregates, their 
modes of dissemination and the biochemical changes that may influence their growth. We show that 
pre-amyloid oligomers (PAO) mature to form linear and circular protofibrils, and amyloid fibers, and 
those can break reforming PAO that can migrate invading neighbor structures. Simulating the effect 
of immunotherapy modifies the dynamics of PAO formation. Anti-fibers as well as anti-PAO antibodies 
fragment the amyloid fibers, however the fragmentation using anti-fibers antibodies favored the 
migration of PAO. In conclusion, we provide evidence for the mechanisms of misfolded protein 
maturation and propagation and the effects of interventions on the resolution and dissemination of 
amyloid pathology.
Diseases of protein folding are growing age-dependent plagues worldwide, and the recognition of their combi-
natory triggers and potential coexistence1,2 is an alarming forthcoming, with the aging of the population. Despite 
the heterogeneity in terms of clinical features as well as time of onset and tissue distribution, age-related disorders 
share a specific pathological signature that is the accumulation of protein aggregates, forming amyloid fibers, that 
drive tissue damage and organ failure. Whether causative or epiphenomenon, malfolded (normal) or misfolded 
(abnormal/mutated) protein aggregation and accumulation has been shown to be an early event in the pathogen-
esis of proteinopathies and, importantly, to cause cell damage and death, disease development and progression3–5. 
Since the pathogenic mechanisms at the origin and progression of these diseases are unclear, there are no effective 
treatments, and a cure is lacking. Major obstacles in the therapeutic approach to proteinopathies include the iden-
tification of the toxic amyloid-related entities, the still unclear nature of the mechanisms of proteotoxicity, and the 
dynamic changes in the process of amyloid fiber formation and dissemination.
In this study we begun addressing some of these unknown using an in-vitro reductionist approach by atomic 
force microscopy (AFM) to study the dynamic events of amyloid de/polymerization and migration. We aimed 
at defining the temporal and spatial dynamic changes of misfolded protein aggregation and fibrillogenesis, and 
their modes of dissemination. This is important because identifying how amyloid develops and the steps from 
misfolded proteins to fibrillar formation, expansion and metastasis will allow tailoring our interventions to each 
of the different maturation and propagation stages. The ultimate goal would be to interfere with the key mecha-
nisms responsible for the development, progression and/or exacerbation of the organs damage and block them.
Results
PAO growth in situ to large ordered amyloid fibers. Misfolding of proteins is known to progress from 
monomeric structures to complex amyloid fibers through reversible maturation steps6–8 (Supplementary Fig. 1). 
Here we interrogated how the different misfolded species thrive. We prepared oligomeric seeds and amyloid fibers 
from purified Aβ 42 peptides as previously described9 and verified by transmission electron microscopy (TEM) 
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(Fig. 1). We immersed slices of mica surface into glass tubes containing PAO in suspension. At intervals from 1 
to 72 hrs the surfaces were pulled out, washed at least three times with ddH2O, blow-dried with argon, placed on 
the AFM platform and promptly measured. This set of experiments confirmed that PAO could be detected on 
mica surfaces (Fig. 2). We followed the maturation of PAO over time. Tapping mode (TM) topography images 
showed, at 1-24 hrs, pseudo spherical PAO (and perhaps larger aggregates) that increased over time in number 
and size (Fig. 2b–d). At times longer than 24 hrs, we observed protofibrils and fibrils (Fig. 2e–g). Also, in this 
case, the number of the structures on mica increased with time. In particular, the maturation of PAO showed the 
formation of linear protofibrils (Fig. 2e) after 48 hrs and small fibrils after 60 hrs (Fig. 2f). These results indicate 
that small PAO may grow at the site where they first originate and progressively mature to coalesce into linear 
protofibrils10–14. Over time fibrillar aggregates may become the amyloid plaques.
PAO budding as a mechanism of tissue invasion. Aβ 42 fragments have been recently shown to be able 
to migrate to the brain in-vivo from a distant site of inoculation, acting as a prion disease1,2,15,16. Here we tested 
whether PAO can move from one surface to the other. We adsorbed PAO on a mica surface by immersion in the 
PAO-containing solution for 24 hrs (here referred as primary mica surface, Iry in the figures) (Fig. 3a,e). The sur-
face was washed at least three times with ddH2O and placed in a glass tube containing phosphate buffered saline 
(PBS). Two sets of experiments were conducted. In a first set, a bare mica surface (here referred as secondary mica 
surface, IIry in the figures), without any treatment, was placed in direct contact with the primary surface, only 
separated by the remaining liquid film (hereafter in contact) (Supplementary Fig. 2). Based on the progression 
of the PAO accumulation of the first set of experiments (Fig. 2), we pulled out the secondary surface at 1, 24 and 
72 hrs time intervals, washed at least three times with ddH2O, blow-dried with argon and imaged with AFM 
(Fig. 3b–d). We found that PAO were able to transfer between the two surfaces in contact as early as 1 hr. At 24 hrs 
PAO density increased and larger protofibrillar structures formed at 72 hrs (Fig. 3b–d).
In a second set of experiments a 0.1 mm thick Teflon thread was placed between the two plates to main-
tain them at a constant separation distance (hereafter in semi-contact). A set of primary and secondary surfaces 
was prepared as before and, at the same time intervals, the secondary surface was pulled out, washed, argon 
blow-dried and imaged with AFM (Fig. 3e–h). Similarly to what was observed without the Teflon thread, the 
secondary mica was coated by pseudo-spherical PAO at short contact times (1–24 hrs, Fig. 3f,g) and linear amy-
loid protofibrils were observed after 72 hrs (Fig. 3h). For both contact and semi-contact experiments, the height 
of PAO and the dimension of protofibrils are in agreement with previously reported data obtained by AFM 
investigations17–19.
These results showed that oligomers can be released from a surface where they strongly adhere and move away 
to attach to another distant surface. Thus these results, in combination with the observation of the maturation of 
PAO to fibers, may explain the dynamics of tissue invasion and spreading as well as the time lapse in the progres-
sion of the disease pathology.
Dynamic fiber depolymerization and re-polymerization as a mechanism of tissue invasion. To 
better understand the spatio-temporal migration of PAO between surfaces we tested how mature fibers that are 
adherent on a surface can release PAO. We tested the concept that amyloid fibers, considered inert, may be indirectly 
toxic by releasing PAO and other misfolded aggregate species in the interstitial tissue poisoning neighbor cells.
We fibrillated the oligomer preparation with hexane as previously described9 and adsorbed the fibrils on a pri-
mary mica surface, as for the PAO, for 1, 6, 12 and 24 hrs to identify the optimal time to visualize the fibrils immo-
bilized on the mica surface and characterize the morphology of the resulting surface (Fig. 4). The results indicated 
an increase in fibril density and length, but not height as a function of time and the appearance of well-defined 
fibers at 24 hrs. This suggests that the adsorption of pre-existing fibrils is the main mechanism involved in the 
Figure 1. PAO and amyloid fibers trasmission electron micrographs of: (a) the PAO synthesized in-vitro;  
(b) the amyloid fibers formed after addition of a 5 v/v% hexane solution to the PAO in suspension.
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aggregation process on the mica surface. Therefore, since the size of fibers remained constant with a high sur-
face density we selected 24 hrs as the time point to adsorb the fibrils on the primary plate for the subsequent 
experiments.
After 24 hrs of exposure, the fibrillar-containing surface was washed and placed in a glass tube containing PBS 
as described above. Fibril migration experiments were performed, with the bare secondary plate put in contact 
(Fig. 5) or semi-contact (Fig. 6) with the primary.
Here we showed that immobilized fibrils are indeed dynamic structures that can release PAO. From the 
primary surface oligomers were budding and deposit on the secondary surface whether the two surfaces were 
in direct contact (Fig. 5) with the primary or physically separated by 0.1 mm of physiological solution filled 
space (Fig. 6). In both experimental conditions, we observed PAO maturation on the secondary plate over time. 
Transitional structures and some annular protofibrils were formed on the secondary surface in direct contact with 
the primary, as early as 1 hr of exposure (Fig. 5a,a1–a4). At 24 hrs we observed numerous multimeric structures 
(Fig. 5b,b1–b4). After 6 days of exposure we could observe the appearance of semicircular and circular fibrils and 
aggregates (Fig. 5c,d).
When the secondary plate was in semi-contact we observed numerous PAO whose number increased between 
1 hr and 6 hrs (Fig. 6a2,a3) and the appearance of transitional and annular structures after 12 hrs of exposure 
(Fig. 6a4 red arrows). Scarce fibrils were also detectable as early as 6 days and more entangled fibers appeared 
after 22 days of exposure (Fig. 6a9,a10 blue arrows). Fibrillar structures deplete from the primary plate over 
time (Fig. 6b1–b6). It is possible that fibrils progressively broke to form the PAO fragments that migrated to the 
secondary surface leaving smaller and less organized protofibrils behind. Those, in turn, may regain higher toxic 
activity. The experiments performed in contact and semi-contact differ not only in the migration rate to the sec-
ondary, but also in number and dimensions of adsorbed species. This suggests that the distance (diffusion time) 
between the depolymerization and repolymerization sites partially affects the nature of the deposited species.
Figure 2. PAO nucleation on primary mica surface. PAO adsorbed on primary (Iry) mica surface followed 
over time. Nucleation of PAO leads to the formation of linear protofibrils after 48 hrs (e). Small fibrils were also 
observed after 60 hrs (f) and at 72 hrs (g). Scale bars: 100 nm (f) and 200 nm (a–e,g). (a) Contact Mode (CM) 
topography image of starting bare mica. (b–g) Tapping Mode (TM) topography images of PAO (b–d) and 
protofibrils/fibrils (e–g) adsorbed on mica after different contact times (1–72 hrs) with a 44 μ M Aβ 42 peptide 
solution in 10 mM PBS at pH 7.4, T = 25 °C. The number and size of the structures are indicated in the table 
under each experimental time point. The amplitude scale is in Volt; we indicated the height (nm) corresponding 
to 1 Volt.
www.nature.com/scientificreports/
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Antibodies treatment affects the rate of formation, maturation and metastasis of misfolded 
proteins. Immunotherapy against Aβ deposits has been recently applied to prevent aggregation or accelerate 
removal of amyloid plaques in the brain. Whereas removing the pathological accumulation of amyloid fibers 
would per se provide a legitimate therapeutic rationale, the concept that PAO fragments, rather than fibrillar 
deposition, are the toxic species, raises the question of whether fibrillar dissolution would favor the fragmentation 
into and the diffusion of the more toxic PAO. In fact, passive immunotherapy using monoclonal antibodies that 
Figure 3. PAO migration. PAO adsorbed on a primary (Iry) mica surface were placed in contact as well in 
semi-contact with a secondary (IIry) surface. TM topography images of the PAO adsorbed on primary placed 
afterwards in contact (a) or in semi-contact (e) with a secondary mica surface and corresponding secondary 
mica at different times (1–72 hrs, contact b–d, semi-contact f–h). The images show the formation of PAO on 
the secondary surface after 1 hr of incubation. The number of PAO on the secondary mica is higher after 24 hrs 
of incubation and linear protofibrils appear after 72 hrs. Scale bars: 100 nm (a) and 200 nm (b–h). PAO were 
adsorbed on the primary mica by dipping the surface for 24 hrs in a 44 μ M Aβ 42 peptide solution in 10 mM PBS at 
pH 7.4, T = 25 °C. The number and size of the structures are indicated in the table under each experimental time 
point. The amplitude scale is in Volt; we indicated the height (nm) corresponding to 1 Volt.
Figure 4. Fibril adsorption on primary mica surface. PAO were fibrillated and adsorbed on primary (Iry) 
mica and followed up to 24 hrs. Images show progressive growth of the number and size of the fibrils. Scale 
bars: 200 nm. PAO were fibrillated as reported in the Methods section. TM topography images show progressive 
growth of the number and size of the fibrils. At all the investigated times, the length of the fibril varies from 80 
to 700 nm. The number and size of the structures are indicated in the table under each experimental time point. 
The amplitude scale is in Volt; we indicated the height (nm) corresponding to 1 Volt.
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target the mid-domain of Aβ peptide recognizing the soluble non-fibrillar form of Aβ has demonstrated improve-
ment of cognitive function in patients with mild AD20. Instead monoclonal antibodies targeting epitopes on fibril-
lar Aβ , disassembling amyloid plaques by activating phagocytosis, failed to show efficacy compared to placebo21. 
Given the dynamic equilibrium between amyloid fibers, intermediate species and PAO and the result of our data 
on fibrillar fragmentation into PAO, we sought at testing whether promoting the dissolution of Aβ fibers would 
increase PAO formation and metastasis. Thus, we repeated the experiments depicted in Fig. 6 using primary mica 
with fibers in semi-contact in the presence of anti-fibrils antibodies (OC22) or anti-Aβ 42PAO antibodies recogniz-
ing the last three amino acids of the Aβ 42 (Val-40, Ile-41, Ala-42 = VIA23). Our results showed that the effect of 
OC antibodies is to fragment the fibrils deposited on the primary mica surface (Fig. 7a1,a3–a5), but at the same 
times it promoted the migration of PAO and the formation of annular protofibrils on the secondary mica surface 
(Fig. 7b). The treatment with VIA antibodies, instead, resulted in fragmentation of the fibers and pulverization of 
the fragments on the primary mica (Fig. 7a2,a6–8). On the secondary mica after 1 hr we observed a limited dep-
osition of oligomeric structures, which undergo fragmentation and pulverization already after 6 hours (Fig. 7c), 
as observed for the primary mica surface.
As control, we imaged mica surfaces immersed in the solution containing OC and VIA antibodies only 
(Supplementary Fig. 3). These experiments showed that OC and VIA antibodies have low affinity for bare mica. 
The imaged antibodies are approximately one tenth for OC and a half for VIA of the surface concentration of 
species detected on secondary mica in the above experiments. This indicates that the adsorbed species on the 
secondary surface are predominantly deriving from the fibers fragmentation and not ascribable to direct antibody 
adsorption. This is further confirmed by the comparison of the height profiles of the antibodies and PAO on sec-
ondary surface, which substantially differ.
Discussion
Amyloid fibers are the larger ordered molecular structures built from repeat units (mer). They form from a 
multistep process by which malfolded (if normal) or misfolded (if mutated) proteins undergo progressive 
Figure 5. PAO budding and migration. Fibrils were adsorbed on primary (Iry) mica surface (scale bar 1 μm). 
An empty secondary (IIry) mica was placed in contact with the primary mica and followed up to 6 days. Contact 
solution: 10 mM PBS at pH 7.4, T = 25 °C. A TM representative topography image of a pristine primary coated with 
fibrils is shown as primary (Iry). (a) Numerous PAO are adsorbed on the secondary mica after 1 hr of contact (scale 
bars: 50 nm (a2,a4) and 100 nm (a1,a3). At this time transitional structures (a2) and scarce annular protofibrils  
(a3–a4) are adsorbed on the IIry. (b) More complex multimeric structures (MS) appear after 24 hrs (scale bars:  
100 nm). The inserts b2 and b4 were magnified with the software therefore do not have the scale bar within the 
figure. (c,d) semi circular, circular (c1–c8) and more structured protofibrils (c4) and transitional structures (d5,d6), 
appear after 6 days (scale bars: 10 nm (d6), 50 nm (c6,c8,d3–d5), 100 nm (c2,c4,c5,c7,d2), and 200 nm (c1,c3,d1)). The 
number and size of the structures are indicated in the table under each experimental time point. The amplitude scale 
is in Volt; we indicated the height (nm) corresponding to 1 Volt.
www.nature.com/scientificreports/
6Scientific RepoRts | 6:35865 | DOI: 10.1038/srep35865
Figure 6. PAO budding and metastasis. (a) Fibrils were adsorbed on primary (Iry) surface (scale bar: 1 μ m). 
Empty secondary (IIry) mica was placed in semi-contact with the primary mica and followed up to 22 days. 
Contact solution: 10 mM PBS at pH 7.4, T = 25 °C. (a1,b1) show the TM topography image of a pristine primary 
coated with fibrils. Here also numerous PAO appear on the secondary surface after 1 hr whose number increases 
at 6 hrs. Complex structures (PAO aggregates/transitional structures and annular protofibrils – red arrows) 
appear as soon as 12 hrs growing in number and complexity at later time points. Scarce simple fibrils (blue 
arrow) appear after 6 days and more complex fibrillar structures (blue arrow) after 22 days (scale bars: 100 nm 
(a5–a7,a10), 200 nm (a8), and 1 μm (a2–a4, a9)). (b) TM topography images of the structure present on the 
primary after semi-contact at different times (1–22 days), the images b2–b6 show a progressive fragmentation 
and reorganization of fibers with time (scale bars: 200 nm (b5,b6) and 1 μm (b2–b4)). The number and size of 
the structures are indicated in the table under each experimental time point. The amplitude scale is in Volt; we 
indicated the height (nm) corresponding to 1 Volt.
www.nature.com/scientificreports/
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Figure 7. Fiber and PAO response to structural antibodies. Treatment with antibodies against amyloid fibers 
(OC) and Aβ 42-PAO (VIA) results in fragmentation of the fibers on the primary surface (a) while PAO and 
circular protofibrils grow on the secondary surface with the anti-fiber antibodies (OC) (b). Treatment with 
antibodies against Aβ 42 PAO (VIA) also led to fibers fragmentation both on primary and secondary surfaces (c). 
(Scale bars: 100 nm (b7–b9,c7–c9), 200 nm (c5), 500 nm (a5,a8,b4–b6,c3,c4,c6), and 1 μm (a1–a4,a6,a7, 
b1–b3,c1,c2)). (a) TM topography images of fibrils adsorbed on a primary and placed in semi-contact for 0, 1 
www.nature.com/scientificreports/
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conformational changes through a process of nucleation-dependent polymerization24–26 (Supplementary Fig. 1). 
This was originally thought to be a biphasic event by which, when misfolded protein monomers reach a critical 
concentration, they precipitate into fibrils in a stable equilibrium. The introduction of atomic force microscopy 
demonstrated the presence of intermediate species, their dynamic formation from monomers and their disap-
pearance as fibers are formed6–8.
A correlate to the dynamic conformation growth is the propagation of the lesion within the tissue, spreading 
the disease. Clinically, amyloid pathology is a spatially progressive process and recent evidence has put forward 
the hypothesis that misfolded proteins may be transmitted between neurons27,28, acting in a prion-like behavior 
in a process named “template protein corruption”29. In this process, misfolded proteins can bind to cognate mol-
ecules and corrupt their conformation, propagating the lesion1,2. Previous evidence also demonstrated that, like 
prion, Aβ 42 aggregates could propagate from peripheral inoculation in the peritoneal cavity causing β -amyloidosis 
to the brain30. Furthermore, very recently it was reported the potential for iatrogenic transmission, supporting 
the possibility that mal/misfolded fragments can maintain their toxic activity in a non-physiological ambient and 
spread from inert substrates to biological targets15,16.
Conform to these reports our data support the notion that aggregated structures can form in a relatively short 
time (hrs) from PAO and that those can progressively grow in number and complexity to more tangled structures. 
The aggregated structures can also be released from inert structures maintaining the potential to carry the path-
ogenic potentials. Furthermore, our findings reveal that PAO can migrate between structures in direct contact 
or at distance recreating and amplifying the pathology. A projection of our data to a physio-pathological setting 
would envision the possibility that PAO can bud from fibers released in the interstitial tissue from diseased cells 
by exocytosis or from dying cells. Those can then decorate the neighbor cells and re-trace the maturation steps to 
form fibers whether in direct contact or through fluid filled spaces. In fact, we also reveal that, although through 
longer time interval, the migration can occur even between structures physically separated. This may represent a 
mechanism for aggregates metastasis in tissues.
Understanding the mechanisms of maturation and spreading of the disease is important not only to learn how 
amyloid plaques, that begin more often in the hippocampus and entorhinal cortex, extend to most brain regions, 
but also to design effective and safe therapeutic approaches.
A still unclear aspect in the pathogenic mechanism of misfolded amyloid species is to which of these structures 
the toxicity is linked. The prevailing wisdom has been, for a while, that the insoluble amyloid fibers are responsible 
for the cellular toxicity. However, the extent of the plaques containing insoluble fibrils, did not correlate with the 
clinical development of the disease in Alzheimer’s dementia, whereas the soluble fraction composed of PAO cor-
relates better with the symptoms of cognitive impairment31. This observation and recent experimental evidence 
has shown, in the neurons and cardiomyocytes, that, for the most part, the PAO and/or a mix of mono-trimers, 
oligomers and protofibrils carry the toxicity to the cell9,32. Thus it is critical to direct the therapeutic effort towards 
targeting the toxic entity e.g. by pushing the equilibrium against or towards fibrillogenesis or both.
The development of structural antibodies against fibers has been, in the recent years, viewed as a promis-
ing therapeutic approach to Alzheimer’s Disease in addition to the more traditional pharmacotherapy directed 
towards neurotransmitters receptors inhibition or activation or neurotransmitters metabolism. Immunotherapy 
against Aβ deposition was introduced in an effort to remove amyloid deposition. However, despite the reduc-
tion in amyloid plaques in the treated patients detected post-mortem, or by PET imaging in living patients, the 
development of meningoencephalic syndrome against a trivial clinical gain, called off clinical trials using immu-
nization33. The rationale for immunotherapy against Aβ in fact mainly stems from in-vitro demonstration that 
antibodies against the N-terminal of the peptide prevent the formation and dissolve preformed fibrils and activate 
microglia to clear opsonized plaques34–36. Subsequently, animal studies indicated that active37 and passive immu-
nization38 - even following a single injection39,40 - in transgenic mice models of AD could remove brain plaques. 
Differently, antibodies against the soluble Aβ - unable to bind fibrillar amyloid - were ineffective in dissolving 
amyloid plaques in-vivo and in-vitro in mice and to activate T-cell response38. However despite a residual plaque 
deposition, memory benefit could be achieved in these mice prompting the hypothesis that a complete removal 
of plaques was not necessary to obtain cognitive benefit41,42. Based on our results we put forward the hypothesis 
that the apparent contradicting correlation between the minimal resolution of plaques and the improvement of 
cognitive function results from targeting the toxic PAO. Thus we designed our experiments to test whether the 
immunization therapy would indeed improve amyloid pathology or, instead, potentially worsen the equilibrium 
towards the toxic species informing to which would be the best theoretical approach to improve disease pathology 
and, overall, the clinical outcome. Our results provide evidence that the antibody treatment of preformed amyloid 
fibers may not reach the desired therapeutic effect. This is because although on one end the treatment indeed 
reduces the plaques as observed in the clinical studies, at the same time, it would potentially increase the release 
and 6 hrs with a secondary using solutions containing structural ≅ 5 μ M OC or VIA antibodies. The image of 
a pristine primary coated with fibrils is shown in a1. For comparison, a2 shows the same surface after 1 hr of 
semi-contact in 10 mM PBS alone. (b,c) TM topography images of a primary after 1 hr and the corresponding 
secondary after 1 hr and 6 hrs using solutions containing OC (b) and VIA (c). For both antibodies, pseudo-
spherical fibril fragments are observed on the primary (a3–a8). After 1 hr of semi-contact with OC antibodies 
(b2,b5,b8), PAO and annular protofibrils grow on the secondary; later (6 hrs, b3,b6,b9) non homogenously 
dispersed pseudo-spherical PAO and aggregates of large dimensions are observed. After 1 hr of semi-contact 
with VIA antibodies (c2,c5,c8) spherical PAO and aggregates form on the secondary, later (6 hrs, c3,c6,c9) a 
deposition of heterogeneous structures arises, some of which reaching the height of 5–8 nm. The number and 
size of the structures are indicated in the table under each experimental time point. The amplitude scale is in 
Volt; we indicated the height (nm) corresponding to 1 Volt.
www.nature.com/scientificreports/
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of the toxic PAO nullifying the benefit acquired by dissolving the fibers. Long-term experiments are mandatory to 
test whether the increased PAO would metastasize and eventually worsen the fiber pathology with newly formed 
foci of amyloid plaques. Our experimental evidence points towards a potential benefit, instead, of immunother-
apy using the anti-PAO antibodies that resulted in extensive fragmentation of the fibers. Thus this approach 
would on one end dissipate the fibers, but also probably dissolve the released PAO in smaller non-toxic fragments 
activating immunity and favoring removal. Long-term follow up experiments dedicated to understanding the fate 
of the fragments will clarify if a therapeutic approach with anti-PAO immunotherapy reduces plaques expansion 
and its dissemination, from the restricted prone regions, more extensively to the brain sectors and would bear 
benefit to the patients.
In conclusion, the dynamic processes, namely the nucleated polymerization and the prion-like propagation as 
well as the iatrogenic transmissibility contribute to the complexity of the pathogenesis of proteinopathies and of 
the therapeutic approaches. Understanding the mechanisms of protein aggregation and organ damage is critical 
to identify when and how to intervene in the different stages of the disease progression. It will also provide targets 
for therapeutic interventions for different progressive and deadly aging-associated diseases and aging itself.
Methods
PAO and fibril synthesis. 1 mg lyophilized Aβ 42 peptide (USBio) was used to prepare PAO as previously 
described9. The peptide was solubilized with acetonitrile and further dissolved by sonication. The peptide’s 
pH was neutralized with NaOH and phosphate buffer. A Phosphate-buffered saline (PBS) solution containing 
0.02 w/v% NaN3 was then added to 1 mg lyophilized Aβ 42 peptide (USBio) dissolved in acetonitrile to reach the 
final volume of 5 ml. After 20 min incubation at room temperature, the samples were centrifuged; the supernatant 
fraction was transferred to another tube and gently bubbled with an argon stream for 10 min to remove the ace-
tonitrile. The complete removal of acetonitrile was verified by gas chromatography-mass spectrometry (GC-MS) 
measurements (Agilent Technologies, 6890N Network GC System, 5973 Network Mass Selective Detector). The 
final pH was checked (SevenEasy pH-meter, Mettler Toledo) and found to be 7.4. The samples were then stirred 
using a Teflon coated micro stir bar for 4 days at 25 °C. Transmission Electron Microscopy was used to confirm 
the formation of PAO (Fig. 1a). Aliquots were used for the AFM experiments. PAO were fibrillated adding a 5 
v/v% hexane solution to the PAO solution, the resulting opalescent suspension was mixed in vortex (Advanced 
Vortex Mixer, VELP Scientifica) for 10 minutes and hexane was removed from the suspension muttering argon 
for 10 minutes. The complete removal of hexane was verified by GC-MS measurements.
Mica surfaces preparation. Several mica slices of 5 × 20 × 0.5 mm were prepared cutting mica sheet by 
hand; each slice was carefully exfoliated before PAO or fibril adsorption to obtain a fresh and renewed plane sur-
face, suited for AFM measurements.
PAO and fibrils adsorption on mica surface (primary). Slices of mica were soaked in a glass tube con-
taining a PBS solution and PAO or fibrils (both deriving from 44 μ M Aβ 42 monomer solutions) for the different 
times of the experimental conditions. After the due time, the slices of mica were pulled out, washed with ddH2O 
and gently blow-dried with argon.
Exposure of a secondary bare mica surface to primary surface containing PAO or fibrils. Experiments 
were conducted approaching a secondary bare mica surface to a primary (coated with PAO or fibrils) in a glass 
tube containing the buffer solution. In the investigated systems, the two facing sheets of mica were either sepa-
rated by just the PBS solution film (contact), or by a 0.1 mm thick Teflon wire placed between the two surfaces in 
a loop shape to maintain constant the distance between the two surfaces (semi-contact).
Different experiments were conducted varying the composition of the medium between the two facing sur-
faces: PBS solution alone, PBS solution containing antibodies effective in recognizing amyloid fibers (OC)2 or Aβ 42 
PAO (VIA)3 (generous gift of Prof. Kayed, UTMD School of Medicine). Typical antibodies concentrations were 
approximately 5 μ M. In the experiments, different contact times were used and both primary and secondary mica 
surfaces were analyzed.
AFM instrument, calibration and experimental conditions. The AFM analysis was performed using 
a VEECO NanoScope IIIa equipped with TAP 150Al-G probe from Budget Sensors; the image collection was 
managed via the software NANOSCOPE IMAGE 5.31R1. All the surfaces were morphologically characterized 
in tapping mode: only bare mica was scanned on contact mode. As our main goal was to observe the structure 
of fibrils and oligomers rather than characterize their atomic structural organization, we preferred working in 
tapping mode with respect to contact mode to avoid tearing or deformation of the sample due to shear forces 
and any damage of the sample due to scraping by the tip. The surfaces of samples were analyzed by non-filtered 
512 pixel/line images. Nonlinear relationship is corrected during the calibration routine by applying a non linear 
voltage in real-time to produce a linear scan in X and Y in both trace and retrace scan directions using a 10 μ m 
pitch calibration grating in which the depth of each square is 200 nm.
After aligning the laser we set the vertical deflection signal of the photo detector to a value close to 0.0 Volts as 
starting value. To be sure that cantilever will vibrate at an appropriate amplitude (i.e., resonance peak is properly 
fixed), we tuned the cantilever before each measurement. We used the auto-tune function of the controlling soft-
ware to determine the frequency that produces the largest response (resonance frequency).
The proper experimental parameters to be used during AFM measurements may vary significantly from point 
to point of the sample surface. For this reason, the scanning of each region starts from predetermined values, 
which are then adjusted during measurement. Three primary feedback parameters were adjusted every time the 
microscope is engaged to capture an image: integral and proportional gains, scan rate, and amplitude set point. 
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For scan sizes up to 1 μ m we fixed the integral gain to 0.4 and the scan rate to 2 Hz as initial scan parameters; at 
the beginning, the amplitude setpoint is automatically set by the software when running auto-tune or before 
engagement if auto-tune is not done. To keep a minimum force between the tip and sample, the amplitude set-
point was gradually optimized increasing its value until the tip lifts off the surface and then decreasing it a little. 
The scan rate was adjusted to a speed adequate to the dimensions of the surface features we wanted to analyze; 
wider scanned surface means lower scan rate values (e.g., 2 Hz for scan sizes of 1–4 μ m). We then increased the 
integral and proportional gains up to the value beyond which the noise will increase as the feedback loop starts to 
oscillate and then we reduced the gains until the noise goes away. Quantitative analysis of the mica surfaces was 
performed on 4–6 images obtained by two different equivalent surfaces. Surface structures with anomalous shape 
or dimension were omitted. Heights are estimated by tracing profiles on the height signal images (GWYDDION 
software, v. 2.34).
Transmission electron microscopy. 5 μ l of the PAO suspension was adsorbed for 1 minute to a formvar/carbon 
coated grid. Excess liquid was removed with filter paper (Whatman #1) and the samples were stained with 1% 
uranyl acetate or 0.75% uranyl formate for 30 seconds. After removing the excess uranyl solution with a filter 
paper the grids were examined in a JEOL 1200EX Transmission Electron Microscope and images were recorded 
with an AMT 2 k CCD camera.
Limitations and future directions. We acknowledge the limitations of the in-vitro study to address bio-
logical processes. We acknowledge that since PAO are unstable and are in constant equilibrium with mono-
mers, dimer-trimers and fibrils24–26 our in-vitro PAO preparation contains a mixed population of monomers, 
dimer-trimers and PAO as verified by size exclusion chromatography (data not shown). However, following 
adsorption of PAO and fibrils on mica, the substrates were dried and the structural features of the adsorbed 
species remained unchanged until they were put in contact with solution. Once in solution the structures begin 
to change and that is one of the goals of the present study. We also acknowledge that the hexane-induced fibril 
formation is not indicative of a physiological condition and the fibrils may have subtle differences in underlying 
structure vs. other methods of generating fibers43. However among the known method to generate in vitro amy-
loid fibers was the one with the least effect on our experimental setting. We chose a reductionist approach to begin 
dissecting the basis for the complex behavior of the dynamic changes of misfolded proteins in a simplified system. 
The findings obtained from this study may help directing future approaches in biological settings. We designed 
future studies to progressively introduce the known variables playing a role in the complex in-vivo system to test 
the mechanisms of PAO metastasis and toxicity to ultimately design targeted interventions.
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